Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer.
The aim of the study was to assess the clinical prognostic value of serum cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) for non-small-cell lung cancer (NSCLC) patients. Literatures related to effects of serum CYFRA21-1 and CEA on the prognosis of lung cancer patients were retrieved from databases such as PubMed, Springer Link, Embase, Wanfang, and CNKI. Meta-analysis was carried out using RevMan 5.1 software. Ten literatures involving 1990 NSCLC patients were selected in this study. Total survive estimation merging hazard ratio (HR) in all NSCLC patients with high-level serum CYFRA21-1 was 1.64 (95% CI 1.46-1.84, P < 0.001) and that in all NSCLC patients with high level serum CEA was 1.46 (95% CI 1.28-1.65, P < 0.001). Serum CYFRA21-1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable.
Department of Thoracic Surgery, Affiliated Hospital of Tai'an Medical University, Tai'an, Shandong, 271000, China.
Zhi-Hui
ZH
Zhang
Department of Oncology, The First Affiliated Hospital of Sichuan Medical University, No. 25 Taiping Street, Luzhou, Sichuan, 646000, China.
Yun-Wei
YW
Han
Department of Medical Imaging, The General Hospital of Jinan Military Command, Jinan, Shandong, 250031, China.
Hui
H
Liang
Department of Thoracic Cardiovascular Surgery, Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, China.
Le-Min
LM
Wang
D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000401:mortality*; D005260:Female; D006801:Humans; D053539:Keratin-19 / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality*; D008297:Male; D011379:Prognosis; D016016:Proportional Hazards Models; D017594:Publication Bias
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D053539:Keratin-19; C102012:antigen CYFRA21.1
Cancer; carcinoembryonic antigen; keratins; meta-analysis; non-small-cell lung cancer; prognosis